Takeda to sell non-core assets for $200M+ — 3 insights

Takeda reached a deal to sell a number of its over-the-counter and prescription pharmaceutical assets to Swiss pharmaceutical company Acino for more than $200 million.

Advertisement

What you should know:

1. Acino will acquire 30 select prescription pharmaceutical and OTC products. The assets are all located in the Near East, Middle East and Africa markets.

2. Takeda is in the process of selling non-core assets to combat the debt it took on during its acquisition of Shire. Takeda became one of the most indebted drugmakers in the world after it acquired Shire.

3. The companies expect the transactions will close in the fourth quarter of 2019.

More articles on surgery centers:
10 states with the highest year-over-year growth in ASCs
6 hospitals, health systems opening or planning ASCs
ASC payer mix, procedure costs & out-of-pocket expenses — 5 statistics

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

Building a High-Performance Cardiac PET Program: What Health Systems Should Consider

Thursday, July 30
12:00 PM - 1:00 PM CDT

Presenters: Rupa Sanghani, MD, FACC, FASNC, Rush University Medical CenterBrendon Loiselle, CDL Nuclear Technologies

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.